Summary
Recent advances in drug delivery technology are creating novel therapeutic approaches to the treatment of Parkinson’s disease with levodopa and dopamine agonists. This article reviews those technologies which can be applied to Parkinson’s disease, both for targetting the central nervous system with drugs, as well as for matching the appropriate rate controlled delivery with therapeutic needs. In particular, the possibility exists for eliminating erratic highs and lows of drug delivery to the brain, and to substitute rate controlled, constant drug delivery. Clinical investigations now in progress suggest that new technologies which deliver constant dopaminergic stimulation to patients with Parkinson’s disease may not only eliminate the unpredictable swings in therapeutic efficacy in Parkinson patients with the “on/off” effect, but may even have a role in the future in preventing such fluctuations from developing in patients chronically treated with dopaminergic therapies.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Bates IP (1984) The blood brain barrier and central nervous system penetration. Pharm J 30: 265–268
Bodor N, Simpkins JW (1983) Redox delivery system for brain-specific sustained release of dopamine. Science 221: 65–67
Costall B, Domeney AM, Naylor RJ (1983) A comparison of the behavioural consequences of chronic stimulation of dopamine receptors in the nucleus accumbens of rat brain effected by a continuous infusion or by single daily injections. Naunyn Schmiedebergs Arch Pharmacol 324: 27–33
Costall B, Domeney AM, Naylor RJ (1984) Locomotor hyperactivity caused by dopamine infusion into the nucleus accumbens of rat brain: specificity of action. Psychopharmacology 82: 174–180
Ensminger W, Niederhuber J, Dakhil S, Thrall J, Wheeler R (1981) Totally implanted drug delivery system for hepatic arterial chemotherapy. Cancer Treat Rep 65: 393–400
Gardner CR (1985) Chemical approaches to drug delivery to the central nervous system. Psychopharmacol Bull 21: 657–662
Goldman P (1982) Rate-controlled drug delivery. N Eng J Med 307: 286–290
Harbaugh RE, Roberts DW, Coombs DW, Saunders RL, Reeder TM (1984) Preliminary report: intracranial cholinergic drug infusion in patients with Alzheimer’s disease. Neurosurgery 15: 514–518
Henderson NL (1983) Recent advances in drug delivery systems technology. In: Allen RC (ed) Annual reports in medicinal chemistry. Academic Press, New York, pp 275–284
Kokkinidis L (1984) Effects of chronic intermittent and continuous amphetamine administration on acoustic startle. Pharmacol Biochem Behav 20: 367–371
Martin-Iverson M, Stahl SM, Iversen SD (1987) Factors determining the behavioural consequences of continuous treatment with 4-propyl-9-hydroxynaphthoxazine, a selective dopamine D2 agonist. In: Rose FC (ed) Parkinson’s disease. J Libbey, London pp 169–177
Mecklenburg RS, Benson EA, Benson JW, Blumenstein BA, Fredlund PM, Guinn TS, Metz RJ, Nielsen RL (1985) Longterm metabolic control with insulin pump therapy. N Eng J Med 313: 465–468
Norstedt G, Palmiter R (1984) Secretory rhythm of growth hormone regulate sexual differentiation of mouse liver. Cell 36: 805–812
Nutt JG, Woodward WR, Hammerstad JP, Carter JH, Anderson JL (1984) The “on-off” phenomenon in Parkinson’s disease: relation to levodopa absorption and transport. N Engl J Med 310: 483–488
Obeso JA, Luquin MR, Martinez-Lage JM (1986 a) Lisuride infusion pump: a device for the treatment of motor fluctuation in Parkinson’s disease. Lancet 1: 467–470
Obeso JA, Luquin MR, Martinez-Lage JM (1986 b) Intravenous lisuride corrects oscillations of motor performance in Parkinson’s disease. Ann Neurol 19: 31–35
Ommaya AK (1984) Implantable devices for chronic access and drug delivery to the central nervous system. Cancer Drug Deliv 1: 169–179
Quinn N, Marsden CD, Parkes JD (1982) Complicated response to intravenous infusion of levodopa. Lancet 2: 412–415
Salzman R, Manson JE, Griffing GT, Kimmerle R, Ruderman N, McCall A, Stoltz EI, Mullin C, Small D, Armstrong J, Melby JC (1985) Intranasal aerosolized insulin: mixed- meal studies and long term use in Type I diabetes. N Engl J Med 312: 1078–1084
Shaw JE, Chandrasekaran SK (1978) Controlled topical delivery of drugs for systemic action. Drug Metab Rev 8: 223–233
Stahl SM (1985) New drug delivery systems-a new approach to Parkinson’s disease. In: Marsden CD, Trimble M (eds) Future trends in the treatment of Parkinson’s disease and epilepsy. Franklin Scientific Projects Publications, London, pp 16–18
Urquhart J, Fara JW, Willis KL (1984) Rate-controlled delivery systems in drug and hormone research. Ann Rev Pharmacol Toxicol 24: 199–236
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1988 Springer-Verlag
About this paper
Cite this paper
Stahl, S.M. (1988). Applications of new drug delivery technologies to Parkinson’s disease and dopaminergic agents. In: Obeso, J.A., Horowski, R., Marsden, C.D. (eds) Continuous Dopaminergic Stimulation in Parkinson’s Disease. Journal of Neural Transmission, vol 27. Springer, Vienna. https://doi.org/10.1007/978-3-7091-8954-2_12
Download citation
DOI: https://doi.org/10.1007/978-3-7091-8954-2_12
Publisher Name: Springer, Vienna
Print ISBN: 978-3-211-82034-6
Online ISBN: 978-3-7091-8954-2
eBook Packages: Springer Book Archive